AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01958476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neonatal Morphine Solution
Description: Infants randomized to this arm will receive neonatal morphine solution (0.2mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than 12. Dosing will be weight and symptom based. A double dummy design will be used - each infant will be ordered for both a methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 4 hours depending on the severity of the Finnegan scores. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS. Infants will be weaned by 10% of the maximum dose once every 24 - 48 hours and the medication will be discontinued once at 25% of the maximum dose.
Study NCT01958476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methadone
Description: Infants randomized to this group will receive methadone oral solution (0.4mg/mL) for first line therapy. Infants will be scored using the standardized Finnegan scoring system and will be initiated on treatment if they have 2 consecutive scores greater than or equal to 8 or 1 score greater than or equal to 12. Dosing will be weight and symptom based. Starting doses will range from 0.3mg/kg/day to 0.9mg/kg/day divided every 8 hours depending on the severity of the Finnegan scores. To maintain blinding of the two study arms, a double dummy design will be used - each infant will receive both methadone/placebo study drug at 0.4 mg/mL and a morphine/placebo study drug at 0.2 mg/mL. Doses will be increased to a maximum of 0.9mg/kg/day for continued scores generally >8 caused primarily by worsening NAS as needed. Infants will be weaned by 10% of the maximum dose once every 24-48 hours and the medication will be discontinued once at 25% of the maximum dose.
Study NCT01958476 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital
Description: A second line medication will be added once the infant reaches maximum doses of the study drug (morphine or methadone) for continued scores generally >8. Infants will be loaded with 20mg/kg of phenobarbital with the option to re-load with 10mg/kg q8-12 hours for 2 more doses if needed for continued high scores. Maintenance therapy of 5mg/kg/day will be initiated 12 - 24 hours after the last loading dose. Phenobarbital trough levels will be monitored with goal levels of 20 - 30 mcg/mL.~Phenobarbital will be weaned only after the infant has been weaned off of the study drug. Weaning will begin 48 hours after the study drug has been stopped by 20% of the maximum total daily dose every 3 days for scores \<8. An infant may be discharged home 48 - 72 hours after the first wean. The remaining wean will be outlined in the discharge prescription, and followed up on by study staff with the goal of the phenobarbital discontinuation within a 2 week period.
Study NCT01887158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Polyethylene glycol
Study NCT01887158 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bisacodyl
Study NCT01903057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azithromycin
Study NCT01903057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: azithromycin
Study NCT02970812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electrical Muscle Stimulation
Description: Participants were under EMS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
Study NCT02970812 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcutaneous Electrical Nerve Stimulation
Description: Participants were under TENS 5 times a week for 12 weeks. Pads were applied on participants' abdomen, rectus abdominis and external oblique abdominal muscle areas without any recent wound, infection, scar, and warts while lie on their back.
Study NCT02339675 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: conventional MS rehabilitation
Description: assessment pre and post conventional MS rehabilitation
Study NCT00049283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00049283 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: docetaxel
Description: Given IV
Study NCT00049283 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Undergo radiotherapy
Study NCT00049283 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Description: Undergo neck dissection
Study NCT00049283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00049283 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03434886 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CFView
Description: Registry patient portal
Study NCT03434886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CFView
Description: Registry patient portal
Study NCT03434886 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CF educational videos
Description: CF educational videos
Study NCT02658188 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8825
Description: Oral
Study NCT01757496 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cough Assist
Study NCT01020539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GVHD Prophylaxis
Description: Can be FK506 (Tacrolimus/Prograf®), mycophenolate mofetil ((MMF)/Cellcept®), or methotrexate (MTX, amethopterin)
Study NCT01020539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemtuzumab Ozogamicin
Description: Dose Escalation
Study NCT01020539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-Thymocyte Globulin
Description: Unrelated Donors only
Study NCT01020539 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: JMML patients only
Study NCT00410436 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Exercise
Description: Subjects demonstrating adequate compliance during the run-in period will then be randomized in equal numbers to Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM), or waiting-list control (C).
Study NCT00410436 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Exercise
Description: Subjects demonstrating adequate compliance during the run-in period will then be randomized in equal numbers to Resistance Training (R) 3X/week progressing to 3 sets, 8 repetitions of 8 exercises at the maximum load that can be lifted 8 times in a controlled manner, maintaining proper form (8RM), or waiting-list control (C).
Study NCT01746069 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quit smoking combined cessation programme
Description: Support sms messages to patient's mobile phone and health advice
Study NCT01746069 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: health advice
Description: routine clinical practice
Study NCT02184442 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR Implantation with SAPIEN XT
Description: Inoperable operable patients requiring the transcatheter aortic heart valve replacement
Study NCT02184442 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TAVR Implantation with SAPIEN
Description: Inoperable operable patients requiring the transcatheter aortic heart valve replacement
Study NCT01473784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transoral robotic surgery
Description: Undergo TORS using the Da Vinci Robotic Surgical System
Study NCT01473784 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality of life assessment
Description: After surgery regular clinical assessments will be scheduled to see how the patient is doing. Patients will be asked to answer a quality of life assessment as part of the study. If patients are unable to come to the Ohio State University Medical Center for a physician appointment they will be contacted via phone or mailed a questionnaire to complete.
Study NCT05324787 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Grency venous stent system
Description: Venous stent implantation during the index procedure
Study NCT01095965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nutrition education
Description: Group education on a bi-weekly basis for eight weeks plus written education materials, followed by monthly group problem solving meetings till one year.
Study NCT00912873 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0.1% Ropivacaine
Description: Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (12mL/h); Basal Dose (12 mg/h); Bolus Volume (4 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)
Study NCT00912873 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.4% Ropivacaine
Description: Ropivacaine 0.1% will be administered via the perineural catheter as follows: Basal Rate (3 mL/h); Basal Dose (12 mg/h); Bolus Volume (1 mL); Bolus Dose (4 mg); Lockout Duration (30 min); Maximum Dose (20 mg/h)
Study NCT01778621 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture(Hwato®)
Description: acupuncture using 4cm long disposable stainless steel hair-thin needles manufactured by Suzhou medical appliance factory (China).
Study NCT00872287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic Cholecystectomy
Description: Four ports classic laparoscopic cholecystectomy
Study NCT00872287 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SILS
Description: Single transumbilical incision laparoscopic cholecystectomy
Study NCT00189878 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate (drug)
Description: Methotrexate 10 to 15 mg weekly for 8 weeks
Study NCT00189878 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo capsules
Description: 4-6 placebo capsules - identical to capsules containing methotrexate
Study NCT04330339 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fasting
Description: Fasting
Study NCT00677300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Raltegravir
Description: 400mg P.O. (orally) twice daily for 48 weeks
Study NCT02391623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an extemporaneously prepared solution every 8 hours for 14 days (n=2).
Study NCT01903057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ivermectin
Study NCT01903057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ivermectin
Study NCT01903057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: albendazole
Study NCT01903057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: albendazole
Study NCT01903057 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT00677300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darunavir
Description: 800 mg P.O. (orally) once daily
Study NCT00677300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darunavir
Description: 800 mg P.O. (orally) once daily
Study NCT00677300 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: 100mg once daily
Study NCT00677300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ritonavir
Description: 100mg once daily
Study NCT00677300 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir/Emtricitabine
Description: 300 mg/200 mg P.O. (orally) once daily
Study NCT04192838 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic incisional ventral hernia repair
Description: Laparoscopic repair of incisional ventral hernias (5-15 cm) with adouble-layer polypropylene- expanded polytetrafluoroethylene (ePTFE) mesh.
Study NCT04192838 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open incisional ventral hernia repair
Description: Standard polypropylene mesh was positioned as an inlay, or as an onlay over the external oblique fascia (i.e., subcutaneously), as preferred by the operating team. The mesh was fixed with absorbable stitches. Drains were usually placed.
Study NCT01018771 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Actifuse ABX
Description: bone graft to be used in posterolateral instrumented lumbar fusion
Study NCT01018771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: INFUSE, plus Mastergraft granules
Description: bone graft to be used in posterolateral instrumented lumbar fusion
Study NCT02956863 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative treatment
Description: Osteopathic manipulative treatment delivered on pragmatic way.
Study NCT02956863 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Exercise for stretching and strength for neck muscles
Study NCT02018679 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Er:YAG AFL-PDT
Description: AFL was performed using a 2940-nm Er:YAG ablative fractional laser (Joule, Sciton Inc., CA, UA) at 550-600 µm ablation in depth, level 1 coagulation, 22% treatment density, and a single pulse. Immediately afterwards, a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2.
Study NCT01903057 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT02039635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Korean Red Ginseng
Description: Given Orally
Study NCT02039635 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given Orally
Study NCT04223349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-70033093
Description: JNJ-70033093 capsules will be administered orally .
Study NCT02018679 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: MAL-PDT
Description: a 1-mm thick layer of MAL (16% Metvix® cream, PhotoCure ASA, Oslo, Norway) was applied to the lesion and to 5 mm of surrounding healthy tissue. The area was covered with an occlusive dressing (Tegaderm, 3M, Saint Paul, MN, US) for 3 hours, after which the remaining cream was removed with saline gauze, and the red fluorescence of porphyrins was visualized with Wood's light. Each treatment area was then separately illuminated with red light-emitting diode (LED) lamps (Aktilite CL128; Galderma, Bruchsal, Germany) with peak emission at 632 nm and total light dose of 37 J cm2. Areas which were scheduled to receive MAL-PDT received the second treatment 7 days later.
Study NCT00637156 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PRESTIGE LP device at two adjacent levels
Description: PRESTIGE LP is a prosthetic device intended to replace a damaged disc in the cervical spine and intended to act as an intervertebral body spacer rather than a fusion device. It is inserted using an anterior surgical approach.
Study NCT00637156 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Bi-level fusion with ATLANTIS Cervical Plate System
Description: Bi-level anterior cervical fusion procedure involving cortical ring allograft and the ATLANTIS Cervical Plate System.
Study NCT01407614 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: external lumbar drainage (ELD) of cerebrospinal fluid
Description: Patients were randomized for external lumbar drainage of cerebrospinal fluid or standard treatment of a subarachnoid hemorrhage alone. External drainage was started within 96 hours of initial subarachnoid hemorrhage during 7 days at a maximum of 5-10 ml/hour.
Study NCT02391623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-06427878
Description: PF-06427878 will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=8).
Study NCT02391623 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered as an extemporaneously prepared solution every 12 hours for 14 days (n=2).
Study NCT01205191 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cell-phone supported CBT
Description: Cognitive behavioural therapy provided with all-time (ubiquitous) support by cell phone applications
Study NCT01205191 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: CBT with digital audio player support
Description: Cognitive behavioural therapy provided with access to a digital audio player with self-administered materials for stress management and relaxation.
Study NCT01205191 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: CBT for anxiety disorders
Study NCT02675101 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Nuts
Description: Participants will be advised on maintaining an iso-caloric diet. Aside consuming nuts, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Both walnuts and almonds will be provided to participants in the whole nut study arm.
Study NCT02675101 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Olestra: Fat Free Pringles
Description: Participants will be advised on maintaining an iso-caloric diet. Aside consuming fat free potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Fat Free Pringles will be provided to participants in the olestra study arm.
Study NCT02675101 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vegetable Oil: Original Pringles
Description: Participants will be advised on maintaining an iso-caloric diet. Aside consuming potato crisps, the remaining composition of the prescribed diet will be based on individual preferences. During the 6-month intervention, study subjects will meet with study staff every 2-3 weeks to weigh in, pick up food supplies and complete a questionnaire on compliance. All participants will have contact with the project coordinator/study dietitian a minimum of every 1-2 weeks either in-person, telephone, email and text message contacts for support, behavioral guidance and strategies. Original Pringles will be provided to participants in the vegetable oil study arm.
Study NCT03927534 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Eating
Description: The ME group will be composed by 7 weekly group sessions with a minimum duration of two hours, mixing theoretical contents with practices. Sessions will always be the same day of the week, except for bank holidays or eventualities, and will be conducted by a psychologist specially trained and certified in ME with experience in leading mindfulness groups. Group sizes will range between 10 and 12 participants. At the end of each session, participants will receive theoretical contents and homework activities to be practiced along the week.
Study NCT02237495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexmedetomidine
Description: dexmedetomidine with the dose of 0.4 ug/kg/h is continuously infused right after anesthesia induction and lasts for 12 hrs.
Study NCT02237495 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The vehicle of dexmedetomidine, normal saline is continuously infused right after anesthesia induction and lasts for 12 hrs with the same rate of the treatment arm.
Study NCT02786355 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Frova bougie
Description: Squeezing an Ambu bag and delivering air through a Frova bougie. Measuring mean volumes of air delivered and peak pressures generated.
Study NCT04558645 — intervention group
Intervention type: OTHER
Intervention: Online Survey
Description: Online surveys will be applied to all participants
Study NCT00320385 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: oral lapatinib once daily
Study NCT00320385 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: IV trastuzumab 2mg/kg weekly after 4mg/kg loading dose